Kali Zhou
Transplant Hepatology · Los Angeles, CANPI 1801195235
Payments from drug & device makers
What this record shows
This record is dominated by grants: $50,000 of the $50,258 with a category attached, or 99.5%. Pfizer accounts for 99.5% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2022 at $50,035 and has fallen 99.7% since, to $135 in 2024.
Across 5 payments — averaging $10,052 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Pfizer$50K
- Gilead$146
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$78
- AbbVie$35
Across 1 payment — averaging $30,939 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Gilead$31K
What the payments were for
- Grants$50,00099%
- Food & beverage$2581%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Pfizer | 1 | $50,000 |
| Gilead | 2 | $146 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $78 |
| AbbVie | 1 | $35 |
How this compares
$50,258 in reported general payments places this provider in the 85th percentile of 39 transplant hepatology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VemlidyTenofovir Alafenamide | 84 | $130,352 |
| EliquisApixaban | 12 | $6,513 |
| Carvedilol | 19 | $221 |
| Spironolactone | 18 | $60 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| GileadVemlidy | $146 | $130,35284 claims |
| PfizerEliquis | $50,000 | $6,51312 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 39 transplant hepatology providers in California.
Other transplant hepatology in Los Angeles
- Julio GutierrezLos Angeles$895K
- Pei Lim LeeLos Angeles$79K
- Beshoy YannyLos Angeles$50K
- Jasleen SinghLos Angeles$46K
- Norah TerraultLos Angeles$13K
- Jeffrey KahnLos Angeles$9K
- Brian KimLos Angeles$7K
- Tse Ling FongLos Angeles$6K
- Liyun YuanLos Angeles$4K
- Cynthia CherfaneLos Angeles$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.